Study Serum Level of Zinc In Benign Prostatic Hyperplasia and Prostatic Cancer Patients

Document Type : Original Article(s)

Authors

1 Infectious Diseases and Tropical Medicine Research Center, Department of Pathology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

2 Department of Urology, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

3 School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

4 Student Research Committee, School of Medicine, Isfahan University of Medical Sciences, Isfahan, Iran

Abstract

Background: Hypothesized that zinc level may be a more specific marker due to its high concentration in the prostate peripheral zone. In this regard, a study was conducted to evaluate the serum zinc level in patients with benign prostatic hyperplasia and prostate cancer at Ordibehesht, Noor, and Ali Asghar medical centers in Isfahan.
Methods: In this analytical cross-sectional study which was conducted in three independent health centers in Esfahan, 185 patients were randomly enrolled in the study after meeting inclusion criteria. The participants underwent 12 prostatic biopsies and blood samples were taken in order to assess the serum level of zinc. Then the patients were divided into three groups of BPH, prostatic cancer and a healthy age-matched individuals as control group. One-way ANOVA was used for data analysis.
Findings: The mean serum zinc level in the control group (85.43 ± 12.04 µg/dL) was significantly higher than in the BPH group (80.29 ± 11.10 µg/dL) and the prostate cancer group (76.61 ± 11.31 µg/dL) (P = 0.04). In contrast, the mean PSA level in the control group (2.65 ± 0.6 ng/mL) was significantly lower than in the BPH group (5.71 ± 8.02 ng/mL) and the prostate cancer group (10.73 ± 6.64 ng/mL) (P = 0.002).
Conclusion: The results of the study showed that serum Zn level was significantly lower in patients with prostatic cancer. The findings of this study can be used for health system professionals.

Highlights

Azar Baradaran: Google Scholar 

Mohammad Yazdani: Google Scholar 

Keywords

Main Subjects

References

  1. Gilbert SF. Endoderm. In Sinauer Associates; 2000 [cited 2025 Sep 5]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK10107/
  2. In brief: How does the prostate work? In Institute for Quality and Efficiency in Health Care (IQWiG); 2022 [cited 2025 Sep 5]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK279291/
  3. Costello LC, Feng P, Milon B, Tan M, Franklin RB. Role of zinc in the pathogenesis and treatment of prostate cancer: critical issues to resolve. Prostate Cancer Prostatic Dis 2004; 7(2): 111–7.
  4. Costello LC, Franklin RB. A comprehensive review of the role of zinc in normal prostate function and metabolism; and its implications in prostate cancer. Arch Biochem Biophys 2016; 611: 100–12.
  5. Gupta N, Sudhakar DVS, Gangwar PK, Sankhwar SN, Gupta NJ, Chakraborty B, et al. Mutations in the prostate specific antigen (PSA/KLK3) correlate with male infertility. Sci Rep 2017; 7: 11225.
  6. Forum I of M (US) F. Nutrition Concerns for Aging Populations. In National Academies Press (US); 2010 [cited 2025 Sep 5]. Available from: https://www.ncbi.nlm.nih.gov/books/NBK51837/
  7. Costello LC, Franklin RB. The clinical relevance of the metabolism of prostate cancer; zinc and tumor suppression: connecting the dots. Mol Cancer 2006; 5: 17.
  8. Leslie SW, Soon-Sutton TL, Skelton WP. Prostate Cancer. In: StatPearls. Treasure Island (FL): StatPearls Publishing; 2025 [cited 2025 Sep 5]. Available from: http://www.ncbi.nlm.nih.gov/books/NBK470550/
  9. Testa U, Castelli G, Pelosi E. Cellular and Molecular Mechanisms Underlying Prostate Cancer Development: Therapeutic Implications. Medicines (Basel) 2019; 6(3): 82.
  10. Costello LC, Franklin RB. Novel role of zinc in the regulation of prostate citrate metabolism and its implications in prostate cancer. Prostate 1998; 35(4): 285-96.
  11. Schiliro C, Firestein BL. Mechanisms of metabolic reprogramming in cancer cells supporting enhanced growth and proliferation. Cells 2021; 10(5): 1056.
  12. Cristina NM, Lucia d’Alba. Nutrition and Healthy Aging: Prevention and Treatment of Gastrointestinal Diseases. Nutrients 2021; 13(12): 4337.
  13. Sarwar S, Adil MAM, Nyamath P, Ishaq M. Biomarkers of Prostatic Cancer: An Attempt to Categorize Patients into Prostatic Carcinoma, Benign Prostatic Hyperplasia, or Prostatitis Based on Serum Prostate Specific Antigen, Prostatic Acid Phosphatase, Calcium, and Phosphorus. Prostate Cancer 2017; 2017: 5687212.
  14. Amparore D, DE Cillis S, Granato S, Ortenzi M, Della Corte M, Sica M, et al. Urinary PSA-ZINC biomarker outperforms standard of care in early detection of prostate cancer. Minerva Urol Nephrol 2024; 76(3): 340-50.
  15. Kolenko V, Teper E, Kutikov A, Uzzo R. Zinc and zinc transporters in prostate carcinogenesis. Nat Rev Urol 2013; 10(4): 219–26.
  16. Wang J, Zhao H, Xu Z, Cheng X. Zinc dysregulation in cancers and its potential as a therapeutic target. Cancer Biol Med 2020; 17(3): 612–25.
  17. Skrajnowska D, Bobrowska-Korczak B. Role of Zinc in Immune System and Anti-Cancer Defense Mechanisms. Nutrients 2019; 11(10): 2273.
  18. Wu F, Zhang H, Hao M. Interactions between key genes and pathways in prostate cancer progression and therapy resistance. Front Onco 2025; 15: 1467540.
  19. Zhang Y, Song M, Mucci LA, Giovannucci EL. Zinc supplement use and risk of aggressive prostate cancer: a 30-year follow-up study. Eur J Epidemiol 2022; 37(12): 1251–60.
  20. Karunasinghe N. Zinc in prostate health and disease: a mini review. Biomedicines 2022; 10(12): 3206.
Journal of Isfahan Medical School
Volume 43, Issue 818
2nd Week, August
July and August 2025
Pages 642-647

Files

History

  • Receive Date: 22 April 2025
  • Accept Date: 13 September 2025

Share

How to cite

Statistics